Get adequate sleep and practice healthy lifestyle habits
The Phase 2 trial published in the New England Journal of Medicine in 2023 reported up to 24% average weight loss at 48 weeks at the highest dose the largest number ever recorded for an obesity drug
Differences in trial design, participant populations, treatment duration, and endpoints mean that direct numerical comparisons between retatrutide Phase 2 data and semaglutide Phase 3 data are hypothesis-generating, not definitive
Your clinical team will guide safe, personalized combinations
GHK-Cu research examines effects on collagen synthesis and extracellular matrix remodeling in various tissue types
A knowledgeable provider will start you on an appropriate dose of peptide therapy in Charleston and monitor your response to minimize any potential side effects, ensuring your treatment is both safe and effective